Leerink Partnrs Estimates Sanofi’s Q4 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Research analysts at Leerink Partnrs reduced their Q4 2024 EPS estimates for shares of Sanofi in a report issued on Sunday, October 27th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $0.83 per share for the quarter, down from their prior estimate of $0.94. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2025 earnings at $4.67 EPS.

A number of other equities research analysts have also weighed in on the company. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Finally, Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.36 on Tuesday. Sanofi has a 1-year low of $44.05 and a 1-year high of $58.97. The stock has a market cap of $137.96 billion, a P/E ratio of 27.73, a PEG ratio of 1.55 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a 50-day moving average of $56.08 and a two-hundred day moving average of $51.84.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $2.55 earnings per share.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently made changes to their positions in SNY. Manning & Napier Advisors LLC acquired a new stake in shares of Sanofi during the second quarter worth $13,725,000. Mount Yale Investment Advisors LLC lifted its holdings in Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after acquiring an additional 12,806 shares during the last quarter. Jennison Associates LLC boosted its stake in Sanofi by 18.9% in the first quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after acquiring an additional 30,115 shares during the period. Sei Investments Co. raised its position in shares of Sanofi by 9.3% during the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after purchasing an additional 47,297 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Sanofi by 10.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock worth $14,951,000 after purchasing an additional 29,082 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.